Outstanding balances with AstraZeneca as of December 31, 2024 and December 31, 2025 are as follows:
|
|
|
|
|
|
|
|
|
$ in thousands |
|
AstraZeneca |
|
|
|
As of December 31, |
|
ASSETS |
|
2024 |
|
|
2025 |
|
Total non-current assets |
|
|
- |
|
|
|
- |
|
Trade receivables |
|
|
6,053 |
|
|
|
12,786 |
|
Total current assets |
|
|
6,053 |
|
|
|
12,786 |
|
TOTAL ASSETS |
|
|
6,053 |
|
|
|
12,786 |
|
LIABILITIES |
|
|
|
|
|
|
Non-current financial liabilities |
|
|
- |
|
|
|
- |
|
Total non-current liabilities |
|
|
- |
|
|
|
- |
|
Current financial liabilities |
|
|
- |
|
|
|
- |
|
Deferred income and contract liabilities |
|
|
112,155 |
|
|
|
96,766 |
|
Total current liabilities |
|
|
112,155 |
|
|
|
96,766 |
|
TOTAL LIABILITIES |
|
|
112,155 |
|
|
|
96,766 |
|
Outstanding balances with Bpifrance were as follows:
|
|
|
|
|
|
|
|
|
$ in thousands |
|
Bpifrance |
|
|
|
As of December 31, |
|
ASSETS |
|
2024 |
|
|
2025 |
|
Total non-current assets |
|
|
- |
|
|
|
- |
|
Total current assets |
|
|
- |
|
|
|
- |
|
TOTAL ASSETS |
|
|
- |
|
|
|
- |
|
LIABILITIES |
|
|
|
|
|
|
Non-current financial liabilities |
|
|
4,358 |
|
|
|
4,042 |
|
Total non-current liabilities |
|
|
4,358 |
|
|
|
4,042 |
|
Current financial liabilities |
|
|
12,716 |
|
|
|
7,555 |
|
Total current liabilities |
|
|
12,716 |
|
|
|
7,555 |
|
TOTAL LIABILITIES |
|
|
17,074 |
|
|
|
11,597 |
|
|